Maricann Group Inc. Secures Second-Site Sales Licence in Canada
TORONTO, ONTARIO–(Marketwired – Sept. 5, 2017) – Maricann Group Inc. (CSE:MARI) (“Maricann” or the “Company”) announced today that it has secured a second-site sales licence for its location in Burlington, ON Canada through its wholly owned subsidiary Maricann Inc. The sales licence is the second granted to Maricann by Health Canada, with the first applying to the company’s cultivation and processing facility in Langton, ON. With the granting of the new licence, Maricann is shifting its client services, sales operations and research activities to Burlington.
The establishment of the Burlington site helps Maricann centralize and streamline numerous sales and marketing processes, including potential same day delivery within the Greater Toronto Area, and next day delivery across Canada. Maricann is now moving through the process of establishing its analytical laboratory functions at the Burlington site, to assist in medical research efforts. This is expected to help scale the business at a faster rate.
The new headquarters in Burlington will centralize our sales, marketing and customer services operations under one roof, which will ultimately create greater efficiencies throughout the company. Importantly, In the near future, we expect to conduct analytical testing and bench research onsite. Overall, the move sets up Maricann for much greater future growth.
Benjamin Ward, CEO of Maricann
Maricann will soon be rolling out new service offerings to clients, such as customer service live chat on its website. As part of Maricann’s commitment to maintaining a low carbon footprint, client services will now transition to a 100% paperless system, while still complying with all Health Canada requirements.
About Maricann Group Inc.
Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Toronto, Canada and Munich, Germany, with production facilities in Langton, Ontario, Canada where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada and Dresden, Germany. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a fully funded 517,000 sq. ft. (48,030 sq. m) build out, that when complete will supply 57,245 kg of increased cannabis dry flower production capacity to support existing and future patient growth.
For more information about Maricann, please visit our website at www.maricann.ca.
Original press release: http://www.marketwired.com/press-release/maricann-group-inc-secures-second-site-sales-licence-in-canada-cse-mari-2232440.htm
